UROGEN PHARMA LTD

UroGen insider Mark Schoenberg sells 10,000 shares under a 10‑B5‑1 plan, signalling confidence amid a 20.6% monthly rise and a 52‑week high.

UroGen Pharma’s insider equity grants reveal a strategic shift: zero‑cost options and RSUs for execs aim to align leadership with shareholder value, hinting at confidence amid clinical milestones.

UroGen insider buying signals optimism amid strong clinical data: insider purchases, positive sentiment, and upcoming conference highlight potential upside, but investors should watch regulatory risks.

UroGen insider selling: Mark Schoenberg’s tax‑coverage trades are routine, not a red flag—yet his ongoing buying shows confidence in the company’s uro‑oncology pipeline.